SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Biotechnology Cancer Cures
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (19)4/12/1999 11:52:00 PM
From: Miljenko Zuanic  Read Replies (1) of 226
 
Thanks.

TCLN vascular targeting and VION pro-drug is old staff.
This combination of the mAb-conjugate enzyme is something new (similar to NXTR aptamer-enzymaticRNA combination).

Designed biochemistry at localized area (sound like ARIA) is something (if develop properly) which may change whole story about cytotoxic cancer drugs.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News